---
title: "Larimar Therapeutics, Inc. (LRMR.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LRMR.US.md"
symbol: "LRMR.US"
name: "Larimar Therapeutics, Inc."
industry: "生物技术"
---

# Larimar Therapeutics, Inc. (LRMR.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [larimartx.com](https://larimartx.com) |

## Company Profile

Larimar Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于利用其新型细胞穿透肽技术平台开发罕见疾病的治疗方案。其主要产品候选药物 CTI-1601 目前正在进行针对弗里德里希共济失调（Friedreich’s ataxia）治疗的第二阶段开放标签临床试验，这是一种罕见的、进行性且致命的遗传疾病。该公司总部位于宾夕法尼亚州的巴拉辛伍德

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.02 | 257/604 | - | - | - |
| PB | 1.91 | 164/604 | 2.65 | 2.00 | 0.93 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-29T05:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 9 | 90% |
| Overweight | 1 | 10% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.97 |
| Highest Target | 26.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/LRMR.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LRMR.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LRMR.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.